Immutep (ASX: IMM) today announces the results of a meeting with the US Food and Drug Administration regarding late-stage clinical development plans for its first-in-class large-molecule cancer drug, along with standard-of-care chemotherapy for the treatment of metastatic breast cancer. Mesoblast (ASX: MSB) today announced it had extended the availability of the final US$30 million facility managed by Oaktree Capital Management. The extended facility is part of its US$90 million five-year facility, subject to achieving certain milestones before September 30, 2023. Immuron (ASX: IMC) has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of Travelan. The company said that an Investigational New Drug application to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhoea caused by E.coli is now active.